Literature DB >> 24617731

Cell therapy in reperfused acute myocardial infarction does not improve the recovery of perfusion in the infarcted myocardium: a cardiac MR imaging study.

Lourens F H J Robbers1, Robin Nijveldt, Aernout M Beek, Alexander Hirsch, Anja M van der Laan, Ronak Delewi, Pieter A van der Vleuten, René A Tio, Jan G P Tijssen, Mark B M Hofman, Jan J Piek, Felix Zijlstra, Albert C van Rossum.   

Abstract

PURPOSE: To investigate the effects of cell therapy on myocardial perfusion recovery after treatment of acute myocardial infarction (MI) with primary percutaneous coronary intervention (PCI).
MATERIALS AND METHODS: In this HEBE trial substudy, which was approved by the institutional review board (trial registry number ISRCTN95796863), the authors assessed the effects of intracoronary infusion with bone marrow-derived mononuclear cells (BMMCs) or peripheral blood-derived mononuclear cells (PBMCs) on myocardial perfusion recovery by using cardiac magnetic resonance (MR) imaging after revascularization. In 152 patients with acute MI treated with PCI, cardiac MR imaging was performed after obtaining informed consent-before randomization to BMMC, PBMC, or standard therapy (control group)-and repeated at 4-month follow-up. Cardiac MR imaging consisted of cine, rest first-pass perfusion, and late gadolinium enhancement imaging. Perfusion was evaluated semiquantitatively with signal intensity-time curves by calculating the relative upslope (percentage signal intensity change). The relative upslope was calculated for the MI core, adjacent border zone, and remote myocardium. Perfusion differences among treatment groups or between baseline and follow-up were assessed with the Wilcoxon signed rank or Mann-Whitney U test.
RESULTS: At baseline, myocardial perfusion differed between the MI core (median, 6.0%; interquartile range [IQR], 4.1%-8.0%), border zone (median, 8.4%; IQR, 6.4%-10.2%), and remote myocardium (median, 12.2%; IQR, 10.5%-15.9%) (P < .001 for all), with equal distribution among treatment groups. These interregional differences persisted at follow-up (P < .001 for all). No difference in perfusion recovery was found between the three treatment groups for any region.
CONCLUSION: After revascularization of ST-elevation MI, cell therapy does not augment the recovery of resting perfusion in either the MI core or border zone. © RSNA, 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24617731     DOI: 10.1148/radiol.14131121

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

1.  Adenosine stress perfusion cardiac magnetic resonance imaging in patients undergoing intracoronary bone marrow cell transfer after ST-elevation myocardial infarction: the BOOST-2 perfusion substudy.

Authors:  Andreas Seitz; Kai C Wollert; Gerd P Meyer; Jochen Müller-Ehmsen; Carsten Tschöpe; Andreas E May; Klaus Empen; Emmanuel Chorianopoulos; Benedikta Ritter; Jens Pirr; Lubomir Arseniev; Hans-Gert Heuft; Arnold Ganser; Eed Abu-Zaid; Hugo A Katus; Stephan B Felix; Meinrad P Gawaz; Heinz-Peter Schultheiss; Dennis Ladage; Johann Bauersachs; Heiko Mahrholdt; Simon Greulich
Journal:  Clin Res Cardiol       Date:  2019-08-10       Impact factor: 5.460

2.  Microvascular perfusion in infarcted and remote myocardium after successful primary PCI: angiographic and CMR findings.

Authors:  Anne Bethke; Limalanathan Shanmuganathan; Geir Øystein Andersen; Jan Eritsland; David Swanson; Nils Einar Kløw; Pavel Hoffmann
Journal:  Eur Radiol       Date:  2018-07-06       Impact factor: 5.315

Review 3.  Perspectives of induced pluripotent stem cells for cardiovascular system regeneration.

Authors:  Mária Csöbönyeiová; Štefan Polák; L'uboš Danišovič
Journal:  Exp Biol Med (Maywood)       Date:  2015-01-16

4.  Discrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysis.

Authors:  Seon Heui Lee; Jin Hyuk Hong; Kyoung Hee Cho; Jin-Won Noh; Hyun-Jai Cho
Journal:  Stem Cell Res Ther       Date:  2016-10-20       Impact factor: 6.832

Review 5.  Pursuing meaningful end-points for stem cell therapy assessment in ischemic cardiac disease.

Authors:  Maria Dorobantu; Nicoleta-Monica Popa-Fotea; Mihaela Popa; Iulia Rusu; Miruna Mihaela Micheu
Journal:  World J Stem Cells       Date:  2017-12-26       Impact factor: 5.326

6.  The influence of microvascular injury on native T1 and T2* relaxation values after acute myocardial infarction: implications for non-contrast-enhanced infarct assessment.

Authors:  Lourens F H J Robbers; Robin Nijveldt; Aernout M Beek; Paul F A Teunissen; Maurits R Hollander; P Stefan Biesbroek; Henk Everaars; Peter M van de Ven; Mark B M Hofman; Niels van Royen; Albert C van Rossum
Journal:  Eur Radiol       Date:  2017-08-18       Impact factor: 5.315

7.  The time window for therapy with peptide nanofibers combined with autologous bone marrow cells in pigs after acute myocardial infarction.

Authors:  Ming-Yao Chang; Chih-Han Chang; Chien-Hsi Chen; Bill Cheng; Yi-Dong Lin; Chwan-Yau Luo; Hua-Lin Wu; Yu-Jen Yang; Jyh-Hong Chen; Patrick C H Hsieh
Journal:  PLoS One       Date:  2015-03-10       Impact factor: 3.240

8.  Endothelial cell-derived pentraxin 3 limits the vasoreparative therapeutic potential of circulating angiogenic cells.

Authors:  Christina L O'Neill; Jasenka Guduric-Fuchs; Sarah E J Chambers; Michelle O'Doherty; Barbara Bottazzi; Alan W Stitt; Reinhold J Medina
Journal:  Cardiovasc Res       Date:  2016-09-22       Impact factor: 10.787

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.